COMPANY:

Genomic Testing Cooperative

"Genomic Testing Cooperative (GTC)...announced the launch of GTC Interpret, a new web-based platform designed to provide Co-Op member laboratories and partner labs seamless online access to fully analyze genomic data with sophisticated reporting tools. With GTC Interpret, users can now access a wealth of detailed genomic information, all generated through GTC’s cutting-edge, AI-driven Interpretstation software suite...Clients with adequate training can perform AI-assisted cancer diagnosis and classification directly on the platform using a variety of powerful algorithms, including deep learning, random forest, extreme gradient boost, support vector machines, and Bayesian-based modeling."

"BioAI...announced a strategic collaboration with Genomic Testing Cooperative (GTC)...This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories."

"CorePath Laboratories has selected Genomic Testing Cooperative (GTC) as a partner in next-generation sequencing (NGS) diagnostics for hematologic neoplasms and solid tumors in a long-term arrangement. Internalizing GTC's tests has enabled CorePath pathologists to provide comprehensive evaluation of patient samples combining targeted DNA and RNA profiling with integrated pathology testing including morphology, immunohistochemistry (IHC), flow cytometry, cytogenetics, and fluorescence in situ hybridization (FISH) to provide accurate, timely and clinically useful information to clinicians."

"Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting three studies illustrating the power of its proprietary RNA next generation sequencing (NGS) approach in advancing liquid biopsy and tissue-based precision testing."

"Sysmex Inostics Inc...and Genomic Testing Cooperative (GTC), based in Irvine, California, formed a strategic partnership for Sysmex Inostics to commercialize GTC’s tissue and liquid biopsy solid tumors and hematology assay services to biopharma customers. This includes GTC’s Solid Tumor Profile Plus, Liquid Trace Solid Tumor Profile, Liquid Trace Hematology Profile, and Hematology Profile Plus assay services."

"COTA, Inc...announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company. The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data. This strategic and oncology-specific partnership, grounded in deep comprehensive clinical data, will support more precise, personalized cancer research particularly across early discovery and translational epidemiology functions....This latest partnership builds on COTA’s recent announcement with the Clinical Research Data Sharing Alliance (CRDSA) and its broader focus on bringing clarity to cancer care."

"Genomic Testing Cooperative, LCA (GTC) announced the presentation of four innovative studies at the annual American Society of Hematology (ASH) meeting that will be held from December 10 to 13, 2022 in New Orleans, Louisiana...GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace."

"With the publication of a paper validating two artificial intelligence-based algorithms for assisting pathologists in molecular profiling of patients, the Genomic Testing Cooperative (GTC) is fully implementing the technology at all of its member laboratories...The primary algorithm, called RNAnalysis, generates probability scores to help clinicians distinguish between 45 classes of diagnostics. A second algorithm, TraceWork, goes deeper into the data whenever RNAnalysis produces similar high probability scores for more than one diagnostic class."

"HALO Diagnostics, a precision diagnostics leader, has joined forces with the Genomic Testing Cooperative (GTC) to offer innovative, personalized testing to its physician network and 1M+ patients served. This solution combines HALO Diagnostics’ clinical ensemble and image-guided therapies with GTC’s genomic profiling of a patient’s DNA / RNA using liquid biopsy and tissue samples. Together, the companies will help patients on every step of their unique healthcare journey – from detection and diagnosis to prognosis and treatment."

"Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace™. Liquid Trace tests both cfDNA and cfRNA not only improves sensitivity of the liquid biopsy but also provides transcriptome data that is enriched by various tumor markers (CA125, CA 15-3, CEA, etc) and makes it possible to perform liquid immunoprofiling by evaluating levels of CD19, CD20, CD33, CD4, CD8, etc."

"Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as well as its liquid biopsy profiles for both solid tumors and hematology that are designed to provide a wide range of clinically actionable insights about a patient’s tumor."